The RCTs were conducted in the community setting, with interventions mainly delivered by health professionals, and had a short- to medium-term follow up (up to 24 weeks). We evaluated nine RCTs involving a total of 622 participants. We performed a meta-analysis of included trials using Review Manager 5. We assessed the risk of bias by evaluating the domains selection,performance, attrition, detection and reporting bias. Screening for inclusion, data extraction and 'Risk of bias'assessment were carried out by one author and checked by a second. Two authors independently screened titles and abstracts for relevance. We included trials if they were randomised controlled trials (RCT) of CrP supplementation in people who were overweight or obese.We excluded studies including children, pregnant women or individuals with serious medical conditions. We searched The Cochrane Library, MEDLINE, EMBASE, ISI Web of Knowledge, the Chinese Biomedical Literature Database, the China Journal Full text Database and the Chinese Scientific Journals Full text Database (all databases to December 2012), as well as other sources (including databases of ongoing trials, clinical trials registers and reference lists). To assess the effects of CrP supplementation in overweight or obese people. Chromium picolinate (CrP) is advocated in the medical literature for the reduction of bodyweight, and preparations are sold as slimming aids in the USA and Europe, and on the Internet. Obesity is a global public health threat.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |